Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I

NCT01040130 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

151

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: Olodaterol (BI 1744)
DRUG: Olodaterol (BI 1744)
DRUG: Placebo
DRUG: Olodaterol (BI 1744)
DRUG: Olodaterol (BI 1744) Placebo

Sponsor

Boehringer Ingelheim